Related Experiment Videos
Molecular therapy for renal diseases
M S Lipkowitz1, M E Klotman, L A Bruggeman
1Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
Summary
Molecular therapy using nucleic acids offers promise for kidney disease treatment. Overcoming delivery and targeting challenges is crucial for successful organ-specific applications and future clinical translation.
Area of Science:
- Nephrology and Molecular Therapeutics
- Gene Therapy and Nucleic Acid Delivery
- Renal Disease Pathophysiology
Background:
- Molecular therapy via nucleic acids (oligonucleotides, genetic constructs) shows potential for treating renal diseases.
- Significant hurdles exist for organ-specific kidney molecular therapy, including selective targeting, vector development, and defining therapeutic targets.
- Clarifying the genetic and pathophysiologic basis of kidney diseases will reveal specific targets like polycystin, HIV-1, alpha-galactosidase A, insulin, and collagen IV chains.
Purpose of the Study:
- To review the potential and challenges of molecular therapy for renal diseases.
- To identify key barriers to successful kidney-specific molecular therapy.
- To discuss potential molecular targets and therapeutic strategies for progressive renal diseases.
Main Methods:
- Review of current literature on molecular therapy approaches for renal diseases.
- Discussion of challenges in gene delivery, vector development, and target identification for kidney applications.
- Exploration of potential therapeutic targets and strategies, including antisense oligodeoxynucleotides and ribozymes.
Main Results:
- The kidney's accessibility via multiple routes (intrarenal artery, uroexcretory pathways, ex vivo) presents an advantage for molecular therapy delivery.
- Development of tropic vectors and tissue-specific promoters is necessary for restricted kidney expression.
- Further understanding of transport, specificity, and in vivo mechanisms of action for nucleic acid delivery is required.
Conclusions:
- Successful kidney-specific molecular therapy requires addressing challenges in targeting, vector development, and long-term regulated expression.
- Appropriate animal models are essential for demonstrating in vivo efficacy.
- A cautious, thorough approach is needed to avoid premature clinical application and maintain enthusiasm for this promising therapeutic field.